Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological standardization of Cupressus arizonica allergen extract in histamine equivalent prick units
2013-001309-98Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Feb 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cupressus arizonica pollen in cypress pollen allergy and allergic rhinitis (AR), sponsored by LETI Pharma. Primary endpoint: Biological activity equivalence target. Started Feb 2015; status: completed.
02
Drugs
cupressus arizonica pollen
03
Conditions
cypress pollen allergyallergic rhinitis (AR)
Beyond the preview
Go deeper on 2013-001309-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001309-98.